HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term.

Photo by nathan dumlao on Unsplash

On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price target, which reflects a 29.6% upside from its current levels.

Over the years, AbbVie Inc. (NYSE:ABBV) has built an impressive line-up of top-selling drugs. Skyrizi, an immunology treatment for arthritis and psoriasis, recorded a 46.8% growth in its sales in the third quarter of 2025 to $4.7 billion. Rinvoq, another immunology drug, reported $2.18 billion in sales, up 35.3% YoY. Similarly, Humira, which is used to treat plaque psoriasis, posted $993 million in revenues, which showed a staggering 55.4% growth from the previous year.

Due to these exceptional results, AbbVie Inc. (NYSE:ABBV)’s management sees further growth in these drugs’ performance. The company expects Rinvoq to generate $11 billion in revenues by 2027, with Skyrizi projected to reach $20 billion. Though the guidance looks overly ambitious, the company’s strong portfolio and its efforts to expand its pipelines through acquisitions make it achievable. In addition, AbbVie Inc. (NYSE:ABBV)’s pipeline across multiple therapeutic areas is promising as well.

On October 31, AbbVie Inc. (NYSE:ABBV)’s board raised the quarterly dividend by 5.5% to $1.73 per share, up from $1.64. That brings the annual payout to $6.92 per share and marks the company’s 53rd consecutive year of dividend growth.

AbbVie Inc. (NYSE:ABBV) is an American pharmaceutical company known for producing treatments that address a wide range of medical conditions.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 11 Worst Performing Dividend Stocks Year-to-Date.

Disclosure: None.